CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.

In conclusion, our results indicate that overexpression of CXCR4 in NSCLC promotes cisplatin resistance via CXCR4-mediated CYP1B1 upregulation. Thus, it can be used as a potential therapeutic target in NSCLC chemoresistance patients and be used as a clinical predictor of cisplatin response. PMID: 27922681 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27922681?dopt=Abstract

Source: Oncology Reports - December 8, 2016 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study